Illumina – Why I Expect New Highs After the Stock Drop

Illumina (ILMN, i) remains a key supplier in the AI revolution within the biotech sector for me. The more genetic data that drug research requires, the greater the demand for DNA analysis and AI applications based on it. The after-hours stock drop of about 13% following the figures from October 29 does little to change this thesis at first. Although reported revenue missed consensus and organic growth slowed from 6.5% to 4.8%, the company remains on track operationally. In the third quarter, Illumina placed over 80 NovaSeq-X systems, totaling...